Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682226 · ClinicalTrials.gov registry record · Phase 2
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
A Phase 2 study of Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT01682226 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 84 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01682226, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to umbilical cord blood will make the transplant safer.
Conditions Studied
Interventions
- DEVICE CliniMACS Fractionation system (Arm A)
- DEVICE CliniMACS Fractionation system (Arm B)
- BIOLOGICAL Haploidentical donor CD34+ cells
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-09-05 |
| Est. Completion | 2021-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682226
The ClinicalTrials.gov registry entry for NCT01682226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which CliniMACS Fractionation system (Arm A) is the first listed.
NCT01682226 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01682226 about?
NCT01682226 is a clinical study titled "Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies". The purpose of this study is to find out whether the addition of blood stem cells from a close family member, when added to umbilical cord blood will make the transplant safer.
What is the current status of trial NCT01682226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2012-09-05. Estimated completion is 2021-01-08.
What conditions does trial NCT01682226 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndrome.
What interventions are being tested in trial NCT01682226?
The interventions under investigation include: CliniMACS Fractionation system (Arm A) (DEVICE), CliniMACS Fractionation system (Arm B) (DEVICE), Haploidentical donor CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01682226?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01682226 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.